GlassScriptPhysician profile
Diego De La Mora
NPI 1124349667
$1,540.69
in general payments reported to CMS, 2019-2025
17 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $247 · 2023: $311 · 2024: $559 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $477.22 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $183.66 | 2022-2025 | Mounjaro, Jardiance |
| Abbott Laboratories | $118.11 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $109.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.41 | 2022-2024 | Jardiance |
| Pfizer INC. | $88.15 | 2022-2025 | |
| Novo Nordisk INC | $79.15 | 2022-2024 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $74.57 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.54 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $48.56 | 2024-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Glaxosmithkline, LLC. | $48.06 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $38.18 | 2024 | |
| Dexcom, INC. | $23.71 | 2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $23.31 | 2023 | Inspire |
| Janssen Pharmaceuticals, INC | $19.92 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.87 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.62 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego De La Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.